Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Bristol Myers Squibb (BMY) is pushing for Reblozyl’s label expansion despite tough competition and generic pressures.

Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...

Despite not meeting the endpoint, subjects have experienced a meaningful improvement in RBC transfusion independence.